The Pharmacokinetics of Melphalan During Intermittent Therapy of Multiple Myeloma

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1988 Jan 1

PMID 3191937

Citations 5

Authors

U Loos

E Musch

M Engel

J H Hartlapp

E Hugl

H J DENGLER

Affiliations

Soon will be listed here.

Abstract

During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy.

Citing Articles

Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Bohler J, Keller E Clin Pharmacokinet. 1993; 24(5):362-79.

PMID: 8504621 DOI: 10.2165/00003088-199324050-00002.

Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Canada A, Herman L, Kidd K, Robertson C, Trump D Cancer Chemother Pharmacol. 1993; 32(1):73-7.

PMID: 8462127 DOI: 10.1007/BF00685880.

Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Smith D, Jodrell D, Egorin M, Ambinder R, Zuhowski E, Kreis W Cancer Chemother Pharmacol. 1993; 31(5):363-8.

PMID: 7679331 DOI: 10.1007/BF00686149.

Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Gera S, Musch E, Osterheld H, Loos U Cancer Chemother Pharmacol. 1989; 23(2):76-80.

PMID: 2910515 DOI: 10.1007/BF00273521.

Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.

Marinelli A, Van Dierendonck J, van Brakel G, Irth H, Kuppen P, Tjaden U Br J Cancer. 1991; 64(6):1069-75.

PMID: 1764369 PMC: 1977872. DOI: 10.1038/bjc.1991.466.

References

Taha I, Ahmad R, Gray H, ROBERTS C, Rogers H . Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol. 1982; 9(1):57-60. DOI: 10.1007/BF00296764. View

Taha I, Ahmad R, Rogers H . Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits. Cancer Chemother Pharmacol. 1981; 5(3):181-4. DOI: 10.1007/BF00258477. View

Ecknauer R, Rommel K . [Cytostatica and small intestine (author's transl)]. Klin Wochenschr. 1978; 56(12):579-92. DOI: 10.1007/BF01477006. View

Woodhouse K, Hamilton P, Lennard A, Rawlins M . The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol. 1983; 24(2):283-5. DOI: 10.1007/BF00613833. View

Bosanquet A, Gilby E . Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother Pharmacol. 1984; 12(3):183-6. DOI: 10.1007/BF00256542. View

Alexanian R, Bonnet J, GEHAN E, Haut A, Hewlett J, Lane M . Combination chemotherapy for multiple myeloma. Cancer. 1972; 30(2):382-9. DOI: 10.1002/1097-0142(197208)30:2<382::aid-cncr2820300213>3.0.co;2-c. View

Brox L, Birkett L, Belch A . Pharmacology of intravenous melphalan in patients with multiple myeloma. Cancer Treat Rev. 1979; 6 Suppl:27-32. DOI: 10.1016/s0305-7372(79)80007-9. View

Kyle R . Multiple myeloma: current therapy and a glimpse of the future. Scand J Haematol. 1985; 35(1):38-47. DOI: 10.1111/j.1600-0609.1985.tb00797.x. View

Evans T, Chang S, Alberts D, Sipes I, Brendel K . In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol. 1982; 8(2):175-8. DOI: 10.1007/BF00255479. View

10.

Bosanquet A, Gilby E . Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol. 1982; 18(4):355-62. DOI: 10.1016/0277-5379(82)90006-2. View

11.

Furner R, Brown R . L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep. 1980; 64(4-5):559-74. View

12.

Alexanian R, Haut A, Khan A, Lane M, MCKELVEY E, MIGLIORE P . Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969; 208(9):1680-5. DOI: 10.1001/jama.208.9.1680. View

13.

Alexanian R, Salmon S, Bonnet J, GEHAN E, Haut A, Weick J . Combination therapy for multiple myeloma. Cancer. 1977; 40(6):2765-71. DOI: 10.1002/1097-0142(197712)40:6<2765::aid-cncr2820400602>3.0.co;2-x. View

14.

GOLDENBERG G, Lam H, Begleiter A . Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chem. 1979; 254(4):1057-64. View

15.

Reece P, Kotasek D, Morris R, Dale B, Sage R . The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol. 1986; 16(2):194-7. DOI: 10.1007/BF00256176. View

16.

Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T . Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Cancer Chemother Pharmacol. 1986; 16(3):300-5. DOI: 10.1007/BF00293997. View

17.

Osterheld H, Musch E, Von Unruh G, Loos U, Rauschecker H, Muhlenbruch B . A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. Cancer Chemother Pharmacol. 1988; 21(2):156-62. DOI: 10.1007/BF00257364. View

18.

Gouyette A, Hartmann O, Pico J . Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol. 1986; 16(2):184-9. DOI: 10.1007/BF00256174. View

19.

Alberts D, Chang S, Chen H, MOON T, Evans T, Furner R . Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979; 26(1):73-80. DOI: 10.1002/cpt197926173. View

20.

Durie B, Salmon S . The current status and future prospects of treatment for multiple myeloma. Clin Haematol. 1982; 11(1):181-210. View